

- Arnold RJ, Gabrail N, Raut M, et al. Clinical implications of chemotherapy-induced diarrhea in patients with cancer. *J Support Oncol* 2005;3:227–232.
- Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. *J Clin Oncol* 1987;5:1559–1565.
- Petrelli N, Douglass HO Jr, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. *J Clin Oncol* 1989;7:1419–1426.
- Meta-Analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. *J Clin Oncol* 1998;16:3537–3541.
- Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. *Clin Colorectal Cancer* 2006;6:288–296.
- Hecht JR. Gastrointestinal toxicity or irinotecan. *Oncology (Williston Park)* 1998;12:72–78.
- Yang X, Hu Z, Chan SY, et al. Novel agents that potentially inhibit irinotecan-induced diarrhea. *Curr Med Chem* 2005;12:1343–1355.
- Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A128 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. *J Clin Oncol* 2006;24:3061–3068.
- de Jong FA, Kehrer DF, Mathijssen RH, et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A128 genotype screening: a double-blind, randomized, placebo-controlled study. *Oncologist* 2006;11:944–954.
- Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. *J Clin Oncol* 2000;18:1337–1345.
- Shepherd FA, Dancy J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *J Clin Oncol* 2000;18:2095–2103.
- Rolston KV. Neutropenic enterocolitis associated with docetaxel therapy in a patient with breast cancer. *Clin Adv Hematol Oncol* 2009;7:527–528.
- Dumitra S, Sideris L, Leclerc Y, et al. Neutropenic enterocolitis and docetaxel neoadjuvant chemotherapy. *Ann Oncol* 2009;20:795–796.
- Calvert AH. Biochemical pharmacology of pemetrexed. *Oncology (Williston Park)* 2004;18:13–17.
- Cloutier RL. Neutropenic enterocolitis. *Emerg Med Clin North Am* 2009;27:415–422.
- Bremer CT, Monahan BP. Necrotizing enterocolitis in neutropenia and chemotherapy: a clinical update and old lessons relearned. *Curr Gastroenterol Rep* 2006;8:333–341.
- Ferrazzi E, Toso S, Zanotti M, et al. Typhilitis (neutropenic enterocolitis) after a single dose of vinorelbine. *Cancer Chemother Pharmacol* 2001;47:277–279.
- Ibrahim NK, Sahin AA, Dubrow RA, et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. *Lancet* 2000;355:281–283.
- D'Amato G, Rocha Lima C, Mahany JJ, et al. Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature. *Lung Cancer* 2004;44:381–390.
- Nesher L, Rolston KV. Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. *Clin Infect Dis* 2013;56:711–717.
- Ullery BW, Pieracci FM, Rodney JR, et al. Neutropenic enterocolitis. *Surg Infect (Larchmt)* 2009;10:307–314.
- Davila ML. Neutropenic enterocolitis. *Curr Treat Options Gastroenterol* 2006;9:249–255.
- Blijlevens NM. Neutropenic enterocolitis: challenges in diagnosis and treatment. *Clin Adv Hematol Oncol* 2009;7:528–530.
- Kirkpatrick ID, Greenberg HM. Gastrointestinal complications in the neutropenic patient: characterization and differentiation with abdominal CT. *Radiology* 2003;226:668–674.
- Cartoni C, Dragoni F, Micozzi A, et al. Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography. *J Clin Oncol* 2001;19:756–761.
- Gorschluter M, Mey U, Strehl J, et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. *Eur J Haematol* 2005;75:1–13.
- Berenson JR, Jagannath S, Barlogie B, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. *Cancer* 2005;104:2141–2148.
- Cohen MH, Johnson JR, Chen YF, et al. FDA drug approval summary: erlotinib (Tarceva) tablets. *Oncologist* 2005;10:461–466.
- Cersosimo RJ. Gefitinib: an adverse effects profile. *Expert Opin Drug Saf* 2006;5:469–479.
- Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. *Clin Cancer Res* 2006;12:7271–7278.
- Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. *Oncologist* 2007;12:107–113.
- Guilhot F. Indications for imatinib mesylate therapy and clinical management. *Oncologist* 2004;9:271–281.
- Simpson D, Curran MP. Temsirolimus: in advanced renal cell carcinoma. *Drugs* 2008;68:631–638.
- Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. *J Clin Oncol* 2009;27:4536–4541.
- Reynolds NA, Wagstaff AJ. Cetuximab: in the treatment of metastatic colorectal cancer. *Drugs* 2004;64:109–118, discussion 119–121.
- Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. *Cancer* 2007;110:980–988.
- Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. *J Clin Oncol* 2007;25:1658–1664.
- Babb RR. Radiation proctitis: a review. *Am J Gastroenterol* 1996;91:1309–1311.
- Bismar MM, Sinicrope FA. Radiation enteritis. *Curr Gastroenterol Rep* 2002;4:361–365.
- Theis VS, Sripadam R, Ramani V, et al. Chronic radiation enteritis. *Clin Oncol (R Coll Radiol)* 2010;22:70–83.
- Kountouras J, Zavos C. Recent advances in the management of radiation colitis. *World J Gastroenterol* 2008;14:7289–7301.
- Kennedy GD, Heise CP. Radiation colitis and proctitis. *Clin Colon Rectal Surg* 2007;20:64–72.
- McFee RB, Abdelsayed GG. Clostridium difficile. *Dis Mon* 2009;55:439–470.
- Ansari J, Choo B, Fernando I. Fatal Clostridium difficile infection associated with vinorelbine chemotherapy: case report and literature review. *J Infect Chemother* 2010;16:210–212.
- Jarvis B, Shevchuk YM. Recurrent Clostridium difficile diarrhea associated with mitoxantrone and etoposide: a case report and review. *Pharmacotherapy* 1997;17:606–611.
- Yamazawa K, Kanno H, Seki K, et al. Life-threatening Clostridium difficile-associated diarrhea induced by paclitaxel-carboplatin combination chemotherapy. *Acta Obstet Gynecol Scand* 2001;80:768–769.
- Huang H, Weintraub A, Fang H, et al. Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of clostridium difficile infections. *J Clin Microbiol* 2009;47:3729–3731.
- Majid HA, Emery PW, Whelan K. Definitions, attitudes, and management practices in relation to diarrhea during enteral nutrition: a survey of patients, nurses, and dietitians. *Nutr Clin Pract* 2012;27:252–260.
- Whelan K, Schneider SM. Mechanisms, prevention, and management of diarrhea in enteral nutrition. *Curr Opin Gastroenterol* 2011;27:152–159.
- Bankhead R, Boullata J, Brantley S, et al. Enteral nutrition practice recommendations. *JPEN J Parenter Enteral Nutr* 2009;33:122–167.
- Chan VW. Chronic diarrhea: an uncommon side effect of celiac plexus block. *Anesth Analg* 1996;82:205–207.
- Cataldo R, Potash M. Atropine as a treatment of diarrhea after celiac plexus block [letter; comment]. *Anesth Analg* 1996;83:1131–1132.
- Cascinu S, Bichisao E, Amadori D, et al. High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. *Support Care Cancer* 2000;8:65–67.
- Hanauer SB. The role of loperamide in gastrointestinal disorders. *Rev Gastroenterol Disord* 2008;8:15–20.
- Topkan E, Karaoglu A. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. *Oncology* 2006;71:354–360.
- Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. *J Clin Oncol* 2004;22:2918–2926.
- Rosenoff S. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. *Support Care Cancer* 2004;12:561–570.
- Mystakidou K, Katsouda E, Tsilika E, et al. Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment. *Anticancer Res* 2006;26:2325–2328.
- Lenfers BH, Loeffler TM, Droege CM, et al. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. *Ann Oncol* 1999;10:1251–1253.
- Karhaus M, Ballo H, Abenhardt W, et al. Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. *Oncology* 2005;68:326–332.
- Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. *Clin Cancer Res* 2009;15:5591–5598.

62. Blesa GMB, Candel VA, Marco VG, et al. Secondary prevention of CPT-11-induced delayed diarrhea with neomycin. *Cancer Ther* 2009;7:282–287.
63. Avigan D, Richardson P, Elias A, et al. Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature. *Cancer* 1998;83:409–414.
64. Urbach DR, Rotstein OD. Typhlitis. *Can J Surg* 1999;42:415–419.
65. Gibson RJ, Keefe DM, Lalla RV, et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. *Support Care Cancer* 2013;21:313–326.
66. Delia P, Sansotta G, Donato V, et al. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. *Am J Gastroenterol* 2002;97:2150–2152.
67. Giral J, Regadera JP, Verges R, et al. Effects of probiotic *Lactobacillus casei* DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. *Int J Radiat Oncol Biol Phys* 2008;71:1213–1219.
68. Kilic D, Egehan I, Ozenirler S, et al. Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy. *Radiother Oncol* 2000;57:125–129.
69. Kilic D, Ozenirler S, Egehan I, et al. Sulfasalazine decreases acute gastrointestinal complications due to pelvic radiotherapy. *Ann Pharmacother* 2001;35:806–810.
70. Yumuk PF, Aydin SZ, Dane F, et al. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients. *Int J Colorectal Dis* 2004;19:609–610.
71. Takeda Y, Kobayashi K, Akiyama Y, et al. [A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation]. *Can To Kagaku Ryoho* 2002;29:1171–1177.
72. Michael M, Brittain M, Nagai J, et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. *J Clin Oncol* 2004;22:4410–4417.
73. Osterlund P, Ruotsalainen T, Korpela R, et al. *Lactobacillus* supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. *Br J Cancer* 2007;97:1028–1034.
74. Meropol N, Blumenson L, Creaven P. Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. *Am J Clin Oncol* 1998;21:135–138.
75. Zachariah B, Gwede CK, James J, et al. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. *J Natl Cancer Inst* 2010;102:547–556.
76. Yehou M, Douillard JY, Rougier P, et al. Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. *Am J Clin Oncol* 2000;23:143–148.
77. Shih DQ, Kwan LY. All roads lead to Rome: update on Rome III criteria and new treatment options. *Gastroenterol Rep* 2007;1:56–65.
78. Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: a systematic review. *J Pain Symptom Manage* 2007;34:94–104.
79. Thorpe DM. Management of opioid-induced constipation. *Curr Pain Headache Rep* 2001;5:237–240.
80. Goodman M, Low J, Wilkinson S. Constipation management in palliative care: a survey of practices in the United Kingdom. *J Pain Symptom Manage* 2005;29:238–244.
81. Mancini I, Bruera E. Constipation in advanced cancer patients. *Support Care Cancer* 1998;6:356–364.
82. Laugsand EA, Jakobsen G, Kaasa S, et al. Inadequate symptom control in advanced cancer patients across Europe. *Support Care Cancer* 2011;19:2005–2014.
83. Staats PS, Markowitz J, Schein J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. *South Med J* 2004;97:129–134.
84. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. *Am J Surg* 2001;182:11S–18S.
85. Holzer P, Ahmedzai SH, Niederle N, et al. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. *J Opioid Manag* 2009;5:145–151.
86. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. *Eur J Pain* 2009;13:56–64.
87. Talley NJ. Serotonergic neuroenteric modulators. *Lancet* 2001;358:2061–2068.
88. Markham A, Sorkin EM. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. *Drugs* 1993;45:931–952.
89. Kellie SJ, Koopmans P, Earl J, et al. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. *Cancer* 2004;100:2637–2643.
90. Haim N, Epelbaum R, Ben-Shahar M, et al. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. *Cancer* 1994;73:2515–2519.
91. Holland J, Scharlau C, Gailani S, et al. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. *Cancer Res* 1973;33:1258–1264.
92. Toghiani PJ, Burke JD. Death from paralytic ileus following vincristine therapy. *Postgrad Med J* 1970;46:330–331.
93. Hwu WJ, Krown SE, Panageas KS, et al. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. *J Clin Oncol* 2002;20:2610–2615.
94. Mancini I, Bruera E. Constipation in advanced cancer patients [see comments]. *Support Care Cancer* 1998;6:356–364.
95. Dukas L, Willett WC, Giovannucci EL. Association between physical activity, fiber intake, and other lifestyle variables and constipation in a study of women. *Am J Gastroenterol* 2003;98:1790–1796.
96. Winge K, Rasmussen D, Werdelin LM. Constipation in neurological diseases. *J Neurol Neurosurg Psychiatry* 2003;74:13–19.
97. Binnie NR, Smith AN, Creasey GH, et al. Constipation associated with chronic spinal cord injury: the effect of pelvic parasympathetic stimulation by the Brindley stimulator. *Paraplegia* 1991;29:463–469.
98. Garvey M, Noyes R Jr, Yates W. Frequency of constipation in major depression: relationship to other clinical variables. *Psychosomatics* 1990;31:204–206.
99. Gray JR. What is chronic constipation? Definition and diagnosis. *Can J Gastroenterol* 2011;25:7B–10B.
100. Nagaviroj K, Yong WC, Fassbender K, et al. Comparison of the Constipation Assessment Scale and plain abdominal radiography in the assessment of constipation in advanced cancer patients. *J Pain Symptom Manage* 2011;42:222–228.
101. Hamilton JW, Wagner J, Burdick BB, et al. Clinical evaluation of methylcellulose as a bulk laxative. *Dig Dis Sci* 1988;33:993–998.
102. Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. *Am J Gastroenterol* 2005;100:936–971.
103. Klaschik E, Nauck F, Ostgathe C. Constipation—modern laxative therapy. *Support Care Cancer* 2005;11:679–685.
104. Brandt LJ, Prather CM, Quigley EM, et al. Systematic review on the management of chronic constipation in North America. *Am J Gastroenterol* 2005;100:S5–S21.
105. Kot TV, Pettit-Young NA. Lactulose in the management of constipation: a current review. *Ann Pharmacother* 1992;26:1277–1282.
106. Kinnunen O, Salokannel J. Constipation in elderly long-stay patients: its treatment by magnesium hydroxide and bulk-laxative. *Ann Clin Res* 1987;19:321–323.
107. Tofil NM, Benner KW, Winkler MK. Fatal hypermagnesemia caused by an Epsom salt enema: a case illustration. *South Med J* 2005;98:253–256.
108. Twycross R, Sykes N, Mihalyo M, et al. Stimulant laxatives and opioid-induced constipation. *J Pain Symptom Manage* 2012;43:306–313.
109. Wald A. Is chronic use of stimulant laxatives harmful to the colon? *J Clin Gastroenterol* 2003;36:386–389.
110. Hurdon V, Viola R, Schroder C. How useful is docusate in patients at risk for constipation? A systematic review of the evidence in the chronically ill. *J Pain Symptom Manage* 2000;19:130–136.
111. Tarumi Y, Wilson MP, Szafran O, et al. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. *J Pain Symptom Manage* 2013;45:2–13.
112. Gondouin A, Manzoni P, Ranfaing E, et al. Exogenous lipid pneumonia: a retrospective multicentre study of 44 cases in France. *Eur Respir J* 1996;9:1463–1469.
113. Gayer G, Gotlieb WH, Apter S. Paraffin oil bezoar impacted in the small bowel: CT findings. *Br J Radiol* 2000;73:1213–1214.
114. Rafati M, Karami H, Salehifar E, et al. Clinical efficacy and safety of polyethylene glycol 3350 versus liquid paraffin in the treatment of pediatric functional constipation. *Daru* 2011;19:154–158.
115. Rauck RL. Treatment of opioid-induced constipation: focus on the peripheral mu-opioid receptor antagonist methylnaltrexone. *Drugs* 2013;73:1297–1306.
116. Yuan CS, Foss JF. Oral methylnaltrexone for opioid-induced constipation. *JAMA* 2000;284:1383–1384.
117. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. *N Engl J Med* 2008;358:2332–2343.
118. Wrenn K. Fecal impaction. *N Engl J Med* 1989;321:658–662.
119. Wald A. Management and prevention of fecal impaction. *Curr Gastroenterol Rep* 2008;10:499–501.
120. Bekkali NL, van den Berg MM, Dijkgraaf MG, et al. Rectal fecal impaction treatment in childhood constipation: enemas versus high doses oral PEG. *Pediatrics* 2009;124:e1108–e1115.